Portfolio Update: Multico and Analabs

One of our pass pick that we are still holding on but we recommend not to add weight due to its extreme diversification plan. It has reported flat revenue and profit of approximately RM 0.11. With a quarter to go, if a slight profit will bring the PE back below 10 times. We always like its auto part industry niche play. However, diversifying into healthcare business is yet to see if it can contribute back to its investment. We continue recommend a hold but we do not plan to buy in more at the moment.

Analabs result is disappointing with gross loss and lower revenue recorded for the quarter. Nothing to cheer with only properties revaluation exercise carried out with net values added to its NTA to RM 3.60. We will continue to monitor its performance from now before making next recommended suggestion.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Create a free website or blog at WordPress.com.

Up ↑

%d bloggers like this: